Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY3471851 in moderately to severely active ulcerative colitis
2020-003017-35Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LY3471851 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Dec 2020; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-003017-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003017-35.